



## Medication-Assisted Treatment (MAT) Services for Opioid Dependence

### Overview

Medication-Assisted Treatment (MAT) is the use of medications, in combination with counseling and behavioral therapies, to provide a “whole-patient” approach to the treatment of substance use disorders.

Buprenorphine is an opioid partial agonist/antagonist that is Food and Drug Administration (FDA) approved for the treatment of opioid dependence by physicians in an office-based setting. Medication of choice is buprenorphine/naloxone for nonpregnant recipients and buprenorphine single ingredient for pregnant recipients.

Reference [Medicaid Services Manual \(MSM\) Chapter 1200, Prescribed Drugs](#), for coverage and limitations.

### Policy

Nevada Medicaid’s policies can be found on the Division of Health Care Financing and Policy (DHCFP) website, <http://dhcfp.nv.gov>, under Medicaid Services Manual (MSM).

MSM Chapter 3800, Medication Assisted Treatment, should be referred to for any policy questions.

Providers eligible to prescribe MAT services must follow the guidelines listed in MSM Chapter 600, Physician Services, for their individual provider type.

### Prior Authorization (PA)

No prior authorization is required for the initiation and maintenance MAT services as listed in MSM Chapter 3800. An individual must meet the medical necessity criteria of MAT services as documented in the recipient’s file.

No prior authorization is required for biopsychosocial assessment.

When referring a recipient for behavioral health services, the individual providing these services must follow the guidelines listed in MSM Chapter 400, Mental Health and Alcohol and Substance Abuse Services, for policies, prior authorization requirements, and service limitations.

### Rates

Rates information is on the DHCFP website at <http://dhcfp.nv.gov> (select “Rates” from the “Resources” menu). Rates are available on the Provider Web Portal at <https://www.medicaid.nv.gov> through the Search Fee Schedule function, which can be accessed on the Electronic Verification System (EVS) Provider Login webpage under Resources (you do not need to login). Any provider-specific rates will not be shown in the Search Fee Schedule function.

### Non-covered Services

When requested for MAT, buprenorphine prescription for any other reason than Opioid Use Disorder (OUD) is not covered.

### Covered Services

Eligible providers with a Drug Enforcement Administration (DEA) license and who meet all of the provider requirements listed in MSM Chapter 3800 would be able to provide and bill for MAT services.

**Medication-Assisted Treatment (MAT) Services for Opioid Dependence****Billing Requirements and Instructions****Screening, Brief Intervention and Referral to Treatment (SBIRT):**

SBIRT is a comprehensive, integrated, public health approach to the delivery of early intervention and treatment services for persons with substance use disorders, as well as those who are at risk of developing these disorders. Screening quickly assesses the severity of substance use and identifies the appropriate level of treatment. Brief intervention focuses on increasing insight and awareness regarding substance use and motivation toward behavioral change. Referral to treatment provides those identified as needing more extensive treatment with access to specialty care.

- Codes are listed in the order of the SBIRT process.
  - Screening: H0049
  - Screening with Brief Intervention (15-30 minutes): 99408\*
  - Screening with Brief Intervention (30+ minutes): 99409\*

\* Distinct evaluation and management (E/M) services that may be reported separately.

**Pre-Induction Visit:**

- Visit type: Adult Wellness visit or acute visit for Opioid Use Disorder/Dependence.
- Comprehensive evaluation of new patient or established patient for suitability for buprenorphine treatment.
  - New Patient: 99205
  - Established Patient: 99215

**Induction Visit:**

- Visit type: MAT medication induction.
- Any of the new patient E/M codes can be used for induction visits.
- Codes are listed in order of increasing length of time with patient and/or severity of the problems.
  - Patient Consult: 99241-99245
- Prolonged visits codes (99354, 99355) may also be added onto E/M codes for services that extend beyond the typical service time. Time spent does not need to be continuous.
  - 30-74 minutes: 99354
  - 75-104 minutes: 99355
  - 105+ minutes: 99354+99355x2

**Maintenance Visits:**

- Visit type: MAT medication. Acute visit for OUD/opioid dependence.
- Any of the established patient E/M codes can be used for maintenance visits.
- Counseling codes are commonly used to bill for maintenance visits, since counseling and coordination of service with addiction specialists comprise the majority of the follow-up visits.
  - Established Patient: 99212-99215

Use modifier U5 and the appropriate OUD diagnosis code with each claim to indicate MAT services.

**Billing for Medications Used for MAT**

**J0571** Buprenorphine, oral, 1 mg

**J0572** Buprenorphine/naloxone, oral, less than or equal to 3 mg



## Billing Instructions

### Medication-Assisted Treatment (MAT) Services for Opioid Dependence

**J0573** Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg

**J0574** Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg

**J0575** Buprenorphine/naloxone, oral, greater than 10 mg

Providers are still required to list the National Drug Codes (NDCs) for the specific drug administered on the claim.

One of the diagnosis codes for J0571 – J0575 must be F11.20, F11.21, F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288 and F11.29.